Keymed Biosciences (SEHK:2162) Stock Questions Whether New Profit Can Last

Simply Wall St.08-21

Keymed Biosciences stock has cooled in recent weeks, with the share price down about 10.6% over the past month even after moving into the black over the last year. Today's earnings story is all about ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2661303292?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-08-21 04:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2661303292","market":"nz","top_or_hot":-1,"title":"Keymed Biosciences (SEHK:2162) Stock Questions Whether New Profit Can Last","media":"Simply Wall St.","content":"<div>\n<p>Keymed Biosciences stock has cooled in recent weeks, with the share price down about 10.6% over the past month even after moving into the black over the last year. Today's earnings story is all about ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-sehk2162-stock-questions-whether-new-prof\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Biosciences (SEHK:2162) Stock Questions Whether New Profit Can Last</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Biosciences (SEHK:2162) Stock Questions Whether New Profit Can Last\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-21 04:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-sehk2162-stock-questions-whether-new-prof><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Keymed Biosciences stock has cooled in recent weeks, with the share price down about 10.6% over the past month even after moving into the black over the last year. Today's earnings story is all about ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-sehk2162-stock-questions-whether-new-prof\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-sehk2162-stock-questions-whether-new-prof","article_id":"2661303292","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-sehk2162-stock-questions-whether-new-prof","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2661303292","pubTimestamp":1787257986,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Keymed Biosciences stock has cooled in recent weeks, with the share price down about 10.6% over the past month even after moving into the black over the last year. Today's earnings story is all about profit, not hype. Basic earnings per share for the first half of 2026 came in at ¥4.29, flipping from losses in 2025, and trailing twelve month earnings now support a P/E of 25.4x.\nThe market is treating that P/E as a question mark. The key issue now is whether investors see this new...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","VOTE":"TCW Transform 500 ETF","BK1161":"生物科技","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","PMDE":"PGIM S&P 500 Max Buffer ETF - December","BK1587":"次新股","BK1574":"生物医药B类股","JOYT":"JPMorgan Equity and Options Total Return ETF","GXDW":"Global X Dorsey Wright Thematic ETF","RGLO":"Global Equity Active ETF","BK1583":"高瓴概念","VGFPF":"Vanguard Funds PLC"},"translate_title":"Keymed Biosciences (SEHK:2162) 股票质疑新利润能否持续","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PMDE":0.87,"FEBU":0.87,"RGLO":0.87,"DECU":0.87,"VOTE":0.87,"JOYT":0.87,"VGFPF":0.87,"GXDW":0.87,"02162":0.9},"content_text":"Keymed Biosciences stock has cooled in recent weeks, with the share price down about 10.6% over the past month even after moving into the black over the last year. Today's earnings story is all about profit, not hype. Basic earnings per share for the first half of 2026 came in at ¥4.29, flipping from losses in 2025, and trailing twelve month earnings now support a P/E of 25.4x. The market is treating that P/E as a question mark. The key issue now is whether investors see this new profitability as durable or as a temporary spike in an expensive biotech stock. Love Keymed Biosciences finally moving into profit but unsure about paying a 25.4x P/E for a biotech stock where earnings durability is still unclear? Check out our 291 resilient stocks with low risk scores that combines earnings support with lower perceived risk. AdvertisementH1 2026 Earnings Summary  Revenue (H1 2026 vs. H1 2025): ¥617.068 million vs. ¥498.752 million (change reflects higher reported revenue year on year) Net Income / Loss (H1 2026 vs. H1 2025): Net income of ¥1,217.447 million vs. a loss of ¥78.843 million (shift to profit from loss) Basic EPS (H1 2026 vs. H1 2025): ¥4.29 per share vs. a loss of ¥0.298288 per share (swing from loss per share to earnings per share) R&D Pipeline Scale (TTM to H1 2026 vs. TTM to H1 2025): 12 products in Phase I, 9 in Phase II, 6 in Phase III, and 1 in pre-registration in the prior trailing period, with current trailing figures not disclosed for comparison (pipeline breadth remains an important driver for Keymed Biosciences)  Prefer clean visual charts instead of scrolling through another page of raw earnings numbers and biotech pipeline tables? See Keymed Biosciences' full financial picture, including a clear view of its valuation, in our company report for Keymed Biosciences. SEHK:2162 Trailing 12-Month Earnings & Revenue History as at Aug 2026 Profit Turning Point Supports Keymed Bull Story For investors focused on pipeline breadth and external validation, Keymed Biosciences now has earnings momentum to match the story. Revenue of ¥617.068 million for H1 2026 sits alongside a clear swing to net profit of ¥1,217.447 million and basic EPS of ¥4.29 per share, compared with losses a year ago. That shift gives the BEL512 Phase II success more financial backing. Profitability combined with a late stage partnered asset heading toward Phase III helps the multi asset, partnership focused narrative look more grounded in the current numbers. Share Pullback Keeps Execution Risks In View The share price has fallen about 10.6% over the past month even as earnings moved into profit, which indicates that investors are not ignoring execution risk. Returns over 90 days are still positive at about 23.8%, so optimism has not disappeared. The AGM plan to expand issuance authority up to 20% of existing share capital highlights ongoing funding needs for BEL512 Phase III and the wider pipeline. The recent profit print softens near term risk perceptions, but dilution and clinical uncertainty remain key watchpoints for Keymed Biosciences. Compare Keymed Biosciences' sharp swing into profit and 25.4x P/E with how the market is pricing its future, and see whether analysts view this as a sustainable turnaround or a one off spike by checking the consensus price target analysis for Keymed Biosciences. Stay Ahead With Simply Wall St If the sharp swing into profit and current 25.4x P/E leave you watching Keymed Biosciences from the sidelines, register for free with Simply Wall St and add it to your Watchlist to track share price against fair value and watch for an entry point that fits your plan. Once you own it, keep your decisions clear with the Portfolio Command Center that filters out noise and highlights only the most important changes to your holdings. For a broader view, tap into crowd insights and different angles on Keymed Biosciences through the Community. This approach may help you identify potential catalysts and risks early while aiming to stay ahead of the market. Seeking Alternatives Beyond Keymed Biosciences? Fresh stock ideas can move fast. Some are building quiet breakout momentum while others may be dropping off the radar. Scan these curated lists before the crowd and consider them carefully.  Target steadier potential by reviewing a curated group of companies with resilient track records using the 291 resilient stocks with low risk scores before prices fully reflect their perceived strength. Explore the early breakout phase in AI by checking hand picked future facing businesses highlighted in the 55 AI infrastructure stocks while they are still under the radar for now. Position yourself ahead of the crowd by assessing companies with solid financial footing through the list of solid balance sheet and fundamentals stocks (434 results) while the window for attractive entry points still looks open.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Keymed Biosciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2661303292","isCrawlerRequest":true}